-
Analysis and Clinical Relevance of Tumor Mutational Burden
Tumor mutational burden (TMB) is a genomic biomarker. In contrast to other biomarkers that are detected as a genomic alteration in a specific gene or via methods like immunohistochemistry, TMB is calculated. However, disagreements about calculation method, clinical indication for immunotherapy, and other factors have hindered establishment of TMB as a standardized biomarker.
-
Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)
-
Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide
-
Currently no job listings
We are always looking for new talent. Feel free to send us your CV. We’d love to get to know you! careers@molecularhealth.com
-
Webinar: IVDR in the laboratory routine – how to make the transition successfully?
Join us for our webinar on the European In Vitro Diagnostics Regulation (IVDR) on Thursday, May 25 at 17:00 CEST.
-
MH Guide 6.0: Next-level automation and precision in the clinical interpretation of cancer genomic profiling
Molecular Health has launched the latest version of its tertiary analysis solution for genomic profiling featuring improved variant classification and more targeted clinical trial matching.
-
Daten töten. Den Krebs.
-
Overcoming IVDR Challenges – A Webinar on November 8, 2022, at 18:00 CET
Join a unique virtual event examining the relevance of the new European In-Vitro Diagnostics Medical Device Regulation (EU)2017/746 (IVDR) for clinical laboratories.
-
Webinar: Deepen your knowledge on comprehensive genomic profiling
Join our educational webinar on comprehensive genomic profiling on Wednesday, October 5 at 6:00 PM CEST.
-
Molecular Health receives IVDR certification for MH Guide
Molecular Health received certification from the European Union for its MH Guide clinical decision support software under the new In Vitro Diagnostics Regulation (EU) 2017/746 (IVDR).
-
MH Guide Webinar – 07.06.2022 12:00 am EST
Join our free-to-attend Live Webinar showcasing how MH Guide translates genomic tumor data into clinical evidence in a few minutes.
-
MH Guide 5.2 – Improved focus. Greater flexibility. Better usability.
New cancer biomarkers are continually found, and additional treatment options are approved. Keep pace with MH Guide 5.2
-
MH Guide Webinar – 28.04.2022 5:00 pm CET
Join our free-to-attend Live Webinar showcasing how to automatically identify clinically actionable biomarkers in molecular tumor profiles.
-
Molecular Health and collaborators prove new analytical approach that leverages real-world data to anticipate molecular causation of adverse drug reactions
Molecular Health, the University of Florida, Takeda Oncology, and thinkQ2 published a triad of articles proving a novel systems approach to elucidate mechanisms of drug toxicities.
-
What’s new in MH Guide 5.1
The MH Guide 5.1 upgrade introduces new features and improved capabilities to access more information and make therapy decisions clearer.
-
Discover the benefits of automated variant annotation for your clinical routine
Automated variant interpretation – fast, precise, efficient MH Guide is an in-vitro diagnostic software approved in Europe. It assists molecular pathologists working with large molecular datasets. Independent of the sequencing technology used, MH Guide can interpret complex datasets and automatically identify genetic variants that are relevant for the treatment of cancer patients. This information is…
-
Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors
-
Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics
-
Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms
-
The COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease
-
The earlier, the better – turning data into knowledge
Automated analysis of hereditary cancer predispositions Our applications for hereditary cancer predispositions are optimized for automated identification of clinically-significant germline variants associated with hereditary breast and ovarian cancers (HBOC), and other hereditary cancer predispositions.
-
基因治療計畫的先驅
將分子學資料轉化為精準醫療MH Guide 是一套分析軟體，輔助病理醫檢師和腫瘤專科醫師解讀龐大的分子學資料集。不論使用何種定序技術，MHGuide 皆能夠有效分析複雜的次世代定序數據，自動識別出與癌症治療有關的基因變異。這些資訊可轉換成臨床知識，協助您規劃個別病患的治療決策。
-
Genome-guided treatment decision support for clinical routines
MH Guide is an analysis software that supports molecular pathologists and oncologists in the interpretation of extensive molecular data sets. MH Guide makes complex NGS data sets readable and automatically identifies relevant genetic variants that are important for the treatment of cancer patients. MH Guide summarizes this information in an intuitive analysis report. For this purpose,…
-
Unlocking patient care and therapy breakthroughs from biomedical knowledge
Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the field of in-silico and precision medicine since 2004. Molecular Health’s solutions enable the transformation of large amounts of data into evidence-based, clinically relevant decision support tools. They are used where complex data interpretation provides access…
-
Pathfinder for genome-based therapy planning
Translate molecular data into precision medicine MH Guide is an analysis software that supports molecular pathologists and oncologists in the interpretation of large molecular datasets. Independent of the sequencing technology used, MH Guide can make complex NGS datasets readable, and automatically identify genetic variants that are relevant for treating cancer patients. This information is translated…
-
Molecular Health and Gen Era Diagnostics agree to collaborate in the field of precision oncology in Turkey
Gen Era Diagnostics will provide the MH Guide software platform to twenty clinical laboratories in Turkey to use in the interpretation of tumor data for personalized cancer care.
-
The potential of liquid biopsies for early cancer detection powered by ONCOCATCH and MH Guide
Molecular Health will join partner EONE-Diagnomics Genome Center (EDGC) in the EDGC seminar.
-
MH Guide 5.0: Software for therapy planning in precision oncology now available with a comprehensive update
The updated MH Guide improves searches for patient-relevant clinical trials and features a conversion tool to integrate data from common next-generation sequencers.
-
Molecular Health and Korean EONE-Diagnomics Genome Center (EDGC) join forces in liquid biopsy-based precision medicine
Molecular Health and EONE-Diagnomics Genome Center establish leadership in the precision medicine market for liquid biopsy, helping healthcare providers identify personalized treatment options for patients.
-
A good perspective for your individual cancer therapy
For those who expect more Using the MH Guide software, laboratories can analyze the exact characteristics of a tumor. For some patients, these insights may result in additional therapy options, suggestions for adjusting the course of therapy, or recommendations for enrolling in a clinical trial.
-
Discover what’s new in MH Guide version 5.0
MH Guide version 5.0 was published with some new features in terms of handling and functionality.
-
Molecular Health and Essen University Hospital launch collaborative project to improve care for COVID-19 patients
In a three-part collaboration with the German Federal Ministry of Health, Molecular Health uses MH Corona Explorer to reveal the molecular basis of COVID-19 disease course.
-
Konyang University Hospital in South Korea relies on MH Guide for personalized cancer medicine
Konyang University Hospital uses MH Guide to perform comprehensive analyses of genes, clinical information, and drugs to provide world-class precision cancer care.
-
Wir bringen die biologische Grammatik in die Medizin
-
Target adverse event profiles for predictive safety in the postmarket setting
-
MH Guide: Molecular tumor diagnostics in 7 steps
The MH Guide software supports therapy decisions in oncology. It can translate data obtained from molecular tumor diagnostic tests into clinically relevant knowledge. This overview illustrates the practical use of the MH Guide.
-
Panel diagnostics instead of hotspot? Here are the differences
NGS, WGS, SNV – What do these abbreviations stand for in molecular pathological diagnostics? What are the benefits of NGS-based panel diagnostics in oncology? This overview provides answers regarding methods of molecular tumor diagnostic testing.
-
Molecular Health – intelligent solutions for smarter healthcare
-
70-year-old with recurrent ovarian cancer
After several therapies and relapses, a 70-year-old female patient with advanced ovarian cancer experienced renewed progression. The use of Molecular Health Guide (MH Guide) provided the molecular tumor board with comprehensive insights and individual therapeutic recommendations.
-
MH Guide: six questions and answers
Tailor-made cancer treatments based on molecular target structures – that’s the premise of personalized tumor therapy. Software-supported solutions like MH Guide can help pinpoint addressable biomarkers as well as treatment options. Read on for answers to the most common questions about MH Guide.
-
Molecular Health and FALCO biosystems team up to provide genetic analysis services using MH Guide/BRCA and MH Guide/Mendel
FALCO biosystems Ltd. will use the products MH Guide/BRCA and MH Guide/Mendel to evaluate inherited genetic variants of BRCA1/2 and other heritable cancer-associated genes.
-
Molekulare Diagnostik beim Mammakarzinom – Wo stehen wir auf dem Weg zur molekular stratifizierten Therapie?
-
Datenprojekt zu Covid-Langzeitfolgen startet
-
Wie der MH Corona Explorer die Versorgung COVID-19-Kranker verbessern soll
-
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development
-
Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports